



## SUVEN PHARMACEUTICALS LTD

Regd. Off: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East,  
Chakala Midc, Mumbai, Maharashtra, India, 400093

STATEMENT OF UNAUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR QUARTER ENDED 30<sup>th</sup> June, 2024.  
₹ Crore

PART - I		STANDALONE			
Sl. No.	PARTICULARS	For the Quarter Ended			For the Year Ended
		30-06-2024	31-03-2024	30-06-2023	31-03-2024
		UN-AUDITED	UN-AUDITED	UN-AUDITED	AUDITED
1	<b>Income</b>				
	Revenue from operations	222.09	243.52	344.03	1,024.99
	Other Income	17.95	16.87	10.06	55.09
	<b>Total income</b>	<b>240.04</b>	<b>260.39</b>	<b>354.09</b>	<b>1,080.08</b>
2	<b>Expenses</b>				
	a) Cost of materials consumed	34.73	63.16	77.62	248.38
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	21.97	17.02	21.50	53.88
	c) Manufacturing Expenses	25.45	35.03	31.18	127.78
	d) Employee benefits expense	43.17	37.10	28.25	126.88
	e) Finance costs	1.60	2.29	1.86	7.43
	f) Depreciation and amortisation expense	12.00	15.66	11.22	48.79
	g) Other Expenses	13.73	19.07	14.81	58.17
	<b>Total expenses</b>	<b>152.65</b>	<b>189.33</b>	<b>186.44</b>	<b>671.31</b>
3	<b>Profit before exceptional items &amp; Tax (1-2)</b>	<b>87.39</b>	<b>71.06</b>	<b>167.65</b>	<b>408.77</b>
4	Exceptional Items				
5	<b>Profit before Tax (3-4)</b>	<b>87.39</b>	<b>71.06</b>	<b>167.65</b>	<b>408.77</b>
6	<b>Tax Expenses</b>				
	a) Current tax	20.02	18.69	41.31	98.14
	b) Deferred tax	2.30	(1.07)	2.04	6.59
	c) Prior year tax	-	-	-	(0.78)
7	<b>Net Profit/ (Loss) for the period/year(5-6)</b>	<b>65.08</b>	<b>53.44</b>	<b>124.30</b>	<b>304.82</b>
8	<b>Other Comprehensive Income</b>				
8.a	(i) Items that will not be reclassified to profit or loss	-	0.72	0.01	(0.39)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	(0.18)	(0.00)	0.10
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	<b>Total other Comprehensive Income</b>	<b>-</b>	<b>0.54</b>	<b>0.01</b>	<b>(0.29)</b>
9	<b>Total Comprehensive Income for the period/year (7+8)</b>	<b>65.08</b>	<b>53.98</b>	<b>124.31</b>	<b>304.53</b>
10	Paid-up equity share capital	25.46	25.46	25.46	25.46
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00
11	Other Equity				2,030.44
12	<b>Earning Per Share (EPS)-Face value of Rs.1/- each)</b>				
	a) Basic	2.56	2.10	4.88	11.97
	b) Diluted	2.56	2.10	4.88	11.97
		(not annualised)	(not annualised)	(not annualised)	(annualised)



PART - II		CONSOLIDATED			
Sl. No.	PARTICULARS	For the Quarter Ended			For the Year Ended
		30-06-2024	31-03-2024	30-06-2023	31-03-2024
		UN-AUDITED	UN-AUDITED	UN-AUDITED	AUDITED
1	<b>Income</b>				
	Revenue from operations	230.69	252.93	347.55	1,051.35
	Other Income	18.16	17.05	10.67	61.91
	<b>Total income</b>	<b>248.85</b>	<b>269.98</b>	<b>358.22</b>	<b>1,113.26</b>
2	<b>Expenses</b>				
	a) Cost of materials consumed	38.30	71.43	79.77	265.88
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	25.30	12.29	21.50	49.15
	c) Manufacturing Expenses	27.08	36.54	32.35	133.48
	d) Employee benefits expense	45.62	39.39	30.72	135.92
	e) Finance costs	1.60	2.30	1.86	7.45
	f) Depreciation and amortisation expense	13.40	17.25	12.61	54.60
	g) Other Expenses	14.46	19.94	15.46	61.11
	<b>Total expenses</b>	<b>165.76</b>	<b>199.14</b>	<b>194.27</b>	<b>707.59</b>
3	Profit before exceptional items , Tax & share in profit/(Loss) of Associates (1-2)	83.09	70.84	163.95	405.67
4	Add : Share of profit/(Loss) of Associates.	-	-	-	-
5	Profit before exceptional items , Tax (3+4)	83.09	70.84	163.95	405.67
6	Exceptional Items				
7	Profit before Tax (5-6)	83.09	70.84	163.95	405.67
8	Tax Expenses				
	a) Current tax	20.02	18.55	41.31	99.58
	b) Deferred tax	2.30	(1.07)	2.04	6.59
	c) Prior year tax	-	-	-	(0.78)
9	Net Profit/ (Loss) for the period/year(7-8)	60.77	53.36	120.60	300.28
10	Other Comprehensive Income				
10.a	(i) Items that will not be reclassified to profit or loss				
	(ii) Equity investments through other comprehensive income - net change in fair value	0.00	0.53	-	0.52
	(iii) Income tax relating to items that will not be reclassified to profit or loss	-	(0.18)	(0.00)	0.10
10.b	(i) Items that will be reclassified to profit or loss	0.04	0.04	-	0.04
	(ii) Exchange differences on translating Investments (carried at FVTOCI)	0.55	12.96	-	12.96
	(iii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	<b>Total other Comprehensive Income</b>	<b>0.59</b>	<b>14.04</b>	<b>0.01</b>	<b>13.20</b>
11	<b>Total Comprehensive Income for the period (9 + 10)</b>	<b>61.36</b>	<b>67.40</b>	<b>120.61</b>	<b>313.48</b>
12	Paid-up equity share capital	25.46	25.46	25.46	25.46
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00
13	Other Equity				2,025.21
14	Earning Per Share (EPS)- (Face value of Rs.1/- each)				
	a) Basic -	2.39	2.10	4.74	11.80
	b) Diluted	2.39	2.10	4.74	11.80
		(not annualised)	(not annualised)	(not annualised)	(annualised)



<p><b>Notes</b></p> <p>1) The above financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 9<sup>th</sup> August, 2024. The above results have been subjected to limited review by the statutory auditors of the company.</p> <p>2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.</p> <p>3) The consolidated financial results include the results of the wholly owned subsidiaries Suven Pharma, Inc., USA &amp; Casper Pharma Pvt Ltd, (w.e.f from 22<sup>nd</sup> April, 2022).</p> <p>4) The Company reportable activity falls under single business segment and hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.</p> <p>5) Pursuant to definitive agreements entered by the company with Sapala Organics Private Limited ("Sapala"), the company has acquired 51% of the share capital on a fully diluted basis (i.e., 67.5% of the present equity share capital) of Sapala on 12<sup>th</sup> July, 2024.</p> <p>6) The Board of Directors had approved on 29<sup>th</sup> February, 2024 the Scheme of Amalgamation of Cohance Life Sciences Limited (Transferor Company) into and with Suven Pharmaceuticals Limited. The Company has received observation letter with "no adverse observations" from BSE Limited on 19<sup>th</sup> July, 2024 and observation letter with "no objection" from the National Stock Exchange of India Limited on 23<sup>rd</sup> July 2024 respectively in relation to the Scheme of Amalgamation. A joint application by the Transferor Company and Suven Pharmaceuticals for the Scheme of Amalgamation has been filed (by way of e-filing) under Sections 230 to 232 of the Companies Act, 2013 and other applicable provisions before the Hon'ble National Company Law Tribunal (NCLT), Mumbai Bench on 25<sup>th</sup> July, 2024. The Scheme of Amalgamation remains subject to applicable approvals, including approvals from the respective jurisdictional Hon'ble NCLT, and such other approvals, permissions, and sanctions of regulatory and other authorities, as may be applicable.</p> <p>7) The board of directors of Suven Pharmaceuticals Limited ("Company"/"Transferee Company") has approved on 29<sup>th</sup> February 2024 the scheme of amalgamation of Casper Pharma Private Limited ("Transferor Company") (a wholly owned subsidiary of the Company) into and with the Company under the provisions of Sections 230 to 232 of the Companies Act, 2013 subject to receipt of applicable approvals including jurisdictional NCLT ("Scheme of Amalgamation"). The Hon'ble NCLT, Mumbai Bench has passed an order dated 14<sup>th</sup> June, 2024 dispensing with the meetings of equity shareholders, secured creditors and unsecured creditors of both the Transferor Company and the Transferee Company and directed, inter-alia the Transferor Company and the Transferee Company to serve notices through registered post on the concerned regulatory authorities for their objections, if any, to the sanctioning of the Scheme of Amalgamation.</p> <p>8) The figures for the quarter ended March 31, 2024 are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2024 and published year to date figures up to third quarter of the financial year ended March 31, 2024, which are subject to limited review by the statutory auditors.</p> <p>9) The corresponding previous period figures have been regrouped/reclassified where ever necessary.</p> <p>10) The Company has chosen to publish the results in ₹ Crore w.e.f quarter ended June 30,2024. Accordingly, the previous quarters figures have been rounded off.</p>	<p><i>mep ob/gj/s</i></p> <p>Dr. V. PRASADA RAJU Managing Director DIN: 07267366</p>
<p>Place : Hyderabad Date : 9<sup>th</sup> August ' 2024</p>	